12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Anacor, Valeant Pharmaceuticals sales and marketing update

Valeant said it will not launch efinaconazole to treat onychomycosis until after its September arbitration hearing to resolve an inherited breach of contract dispute with Anacor. Valeant said it received notice last October that Anacor was commencing arbitration related to a March 2004 master services agreement between Anacor and

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >